Advertisement

Topics

Sproutly Tapped to Present at Canaccord Genuity 3rd Annual Cannabis Conference, Cannastocks2019 Investor Conference & Cannabis Drinks Expo

09:00 EDT 13 May 2019 | Businesswire

Sproutly Canada, Inc.

NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES

Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) (“Sproutly" or the “Company”) executives have been tapped to present at key upcoming conferences:

  • Chief Executive Officer (“CEO”), Keith Dolo, will present at the Canaccord Genuity 3rd annual cannabis conference on May 14th at the Grand Hyatt in New York.
  • CEO Keith Dolo will present as the Cannastocks2019 Q1 investor conference on May 15th, also in New York.
  • Chief Science Officer (“CSO”), Arup Sen, will present at the Cannabis Drinks Expo at the South San Francisco Conference Center in San Francisco on July 25th.

Dolo & Sen’s remarks come on the heels of an announcement on April 30th of a Joint Venture with Moosehead Breweries to launch cannabis-infused beverages in Canada. Sproutly’s mission is to deliver a safe and consistent whole plant experience from cannabis, with a lead position in the beverage market. By combining advanced cannabis cultivation and proprietary “APP” technology, Sproutly intends to redefine the cannabis industry. Aqueous Phytorecovery Process (“APP”) is a patent pending process that naturally produces water soluble cannabinoids known as ‘Infuz2O’ as well as BioNatural Oil.

Sproutly will also be a featured exhibitor at the Lift & Co Expo from June 6-9th at the Metro Toronto Convention Center in Toronto.

About Sproutly Canada, Inc.

Sproutly’s core mission is to become the leading supplier to the cannabis beverage and edibles market. Our Toronto based, ACMPR licensed facility was built to cultivate pharmaceutical grade cannabis to supply a technological breakthrough in producing and formulating the first natural, truly water-soluble cannabis solution. Our water-soluble ingredients and our bio-natural oils will deliver revolutionary brands to international markets that are clamouring for well-defined commercial products. Sproutly’s business focus is to execute on partnerships with local and globally established consumer brands to leverage their existing customer bases, further expand brand loyalty, assist with marketing, and support distribution networks to deliver this scientific breakthrough with speed and efficiency worldwide.

For more information on Sproutly, please visit: www.sproutly.ca.

Forward-Looking Statements

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or believes regarding future events of management of Sproutly Canada. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things, the expected launch of the Company’s first line of beverage products. These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These assumptions, risks and uncertainties include, among other things, the Company successfully completing the development and production of its first line of beverage and cannabis products and obtaining all applicable regulatory approvals from global jurisdictions including Health Canada. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended, such as the Company’s inability to successfully develop and produce its first line of beverage products or the Company’s inability to obtain any necessary regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

Contact: Keith Dolo, Chief Executive Officer of Sproutly Canada
Email: investors@sproutly.ca

NEXT ARTICLE

More From BioPortfolio on "Sproutly Tapped to Present at Canaccord Genuity 3rd Annual Cannabis Conference, Cannastocks2019 Investor Conference & Cannabis Drinks Expo"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.